Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

Current Opinion in Pharmacology

Volumn 4, Issue 6, 2004, Pages 589-596

  Holst, Jens Juul ^a   Deacon, Carolyn F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBUGON; ALBUMIN; ANTIDIABETIC AGENT; CHEMOKINE; CJC 1131; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FE 999 011; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOLEUCINE THIAZOLIDIDE; LIRAGLUTIDE; METFORMIN; NEUROPEPTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; POLYPEPTIDE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE PYRROLIDIDE; VILDAGLIPTIN;

ALZHEIMER DISEASE; APOPTOSIS; APPETITE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG TOLERABILITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SYNTHESIS; NAUSEA; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PRURITUS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GREAT BRITAIN; HUMANS; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN PRECURSORS;

EID: 14044264798     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.08.005     Document Type: Review

References (70)

1. J.J. Holst J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab 287 2004 E199-E206
2. M. Nauck F. Stockmann R. Ebert W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1986 46-52
3. T. Vilsboll J.J. Holst Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia 47 2004 357-366
4. L.L. Kjems J.J. Holst A. Volund S. Madsbad The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects Diabetes 52 2003 380-386
5. T. Vilsboll F.K. Knop T. Krarup A. Johansen S. Madsbad S. Larsen T. Hansen O. Pedersen J.J. Holst The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype J Clin Endocrinol Metab 88 2003 4897-4903
6. J. Rachman B.A. Barrow J.C. Levy R.C. Turner Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205-211
7. M. Gutniak C. Orskov J.J. Holst B. Ahren S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus N Engl J Med 326 1992 1316-1322
8. J.J. Holst Therapy of type 2 diabetes mellitus based on the actions of glucagon- like peptide-1 Diabetes Metab Res Rev 18 2002 430-441
9. H.C. Fehmann J.F. Habener Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells Endocrinology 130 1992 159-166
10. J. Buteau R. Roduit S. Susini M. Prentki Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells Diabetologia 42 1999 856-864
11. J.M. Egan A. Bulotta H. Hui R. Perfetti GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells Diabetes Metab Res Rev 19 2003 115-123
12. G. Xu D.A. Stoffers J.F. Habener S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270-2276
13. D.A. Stoffers T.J. Kieffer M.A. Hussain D.J. Drucker S. Bonner-Weir J.F. Habener J.M. Egan Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 49 2000 741-748
14. J. Zhou X. Wang M.A. Pineyro J.M. Egan Glucagon-like peptide 1 and exendin-4 convert pancrteatic AR42J cells into glucagon- and insulin-producing cells Diabetes 48 1999 2358-2366
15. R. Perfetti J. Zhou M.E. Doyle J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic- duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600-4605
16. J. Buteau W. El-Assaad C.J. Rhodes L. Rosenberg E. Joly M. Prentki Glucagon-like peptide-1 prevents beta cell glucolipotoxicity Diabetologia 47 2004 806-815
17. M.B. Toft-Nielsen M.B. Damholt S. Madsbad L.M. Hilsted T.E. Hughes B.K. Michelsen J.J. Holst Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients J Clin Endocrinol Metab 86 2001 3717-3723
18. A. Wettergren B. Schjoldager P.E. Mortensen J. Myhre J. Christiansen J.J. Holst Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig Dis Sci 38 1993 665-673
19. M.A. Nauck U. Niedereichholz R. Ettler J.J. Holst C. Orskov R. Ritzel W.H. Schmiegel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 273 1997 E981-E988
20. A. Young M. Denaro Roles of amylin in diabetes and in regulation of nutrient load Nutrition 14 1998 524-527
21. C. Verdich A. Flint J.P. Gutzwiller E. Naslund C. Beglinger P.M. Hellstrom S.J. Long L.M. Morgan J.J. Holst A. Astrup A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans J Clin Endocrinol Metab 86 2001 4382-4389
22. B.P. Bullock R.S. Heller J.F. Habener Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 137 1996 2968-2978
23. R. Gros X. You L.L. Baggio M.G. Kabir A.M. Sadi I.N. Mungrue T.G. Parker Q. Huang D.J. Drucker M. Husain Cardiac function in mice lacking the glucagon-like peptide-1 receptor Endocrinology 144 2003 2242-2252
24. Bose KA, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide-1(GLP-1) can directly protect the heart against ischemia/reperfusion injury. Diabetes 2004, in press
25. L.A. Nikolaidis S. Mankad G.G. Sokos G. Miske A. Shah D. Elahi R.P. Shannon Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962-965
26. H. Yamamoto C.E. Lee J.N. Marcus T.D. Williams J.M. Overton M.E. Lopez A.N. Hollenberg L. Baggio C.B. Saper D.J. Drucker J.K. Elmquist Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons J Clin Invest 110 2002 43-52
27. H. Yamamoto T. Kishi C.E. Lee B.J. Choi H. Fang A.N. Hollenberg D.J. Drucker J.K. Elmquist Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites J Neurosci 23 2003 2939-2946
28. M. Zander S. Madsbad J.L. Madsen J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study Lancet 359 2002 824-830
29. T. Perry N.J. Haughey M.P. Mattson J.M. Egan N.H. Greig Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4 J Pharmacol Exp Ther 302 2002 881-888
30. M.J. During L. Cao D.S. Zuzga J.S. Francis H.L. Fitzsimons X. Jiao R.J. Bland M. Klugmann W.A. Banks D.J. Drucker C.N. Haile Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat Med 9 2003 1173-1179
31. T.A. Perry N.H. Greig A new Alzheimer's disease interventive strategy: GLP-1 Curr Drug Targets 5 2004 565-571
32. T. Vilsboll H. Agerso T. Krarup J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 88 2003 220-224
33. M.R.W. Ehlers E.H. Roderick R.L. Schneider M.S. Kipnes Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes [abstract] Diabetes 51 Suppl 2 2002 A579
34. C.F. Deacon L.B. Knudsen K. Madsen F.C. Wiberg O. Jacobsen J.J. Holst Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity Diabetologia 41 1998 271-278
35. J.J. Meier M.A. Nauck D. Kranz J.J. Holst C.F. Deacon D. Gaeckler W.E. Schmidt B. Gallwitz Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects Diabetes 53 2004 654-662
36. C.M. Edwards S.A. Stanley R. Davis A.E. Brynes G.S. Frost L.J. Seal M.A. Ghatei S.R. Bloom Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab 281 2001 E155-E161
37. M.S. Fineman T.A. Bicsak L.Z. Shen K. Taylor E. Gaines A. Varns D. Kim A.D. Baron Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diabetes Care 26 2003 2370-2377
38. R. Hiles T. Carpenter D. Serota K. Schafer P. Ross D. Nelsen M. Rebelatto Exenatide does not cause pancreatic tumours or malignancies in rats and mice following a 2-year period of exposure [abstract] Diabetes 53 Suppl 2 2004 A380
39. J. Larsen B. Hylleberg K. Ng P. Damsbo Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment Diabetes Care 24 2001 1416-1421
40. L.B. Knudsen H. Agersø C. Bjenning S. Bregenholt C. Gotfredsen J.J. Holst P.O. Huusfeldt M.Ø. Larsen P.J. Larsen P.F. Nielsen et al. GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes Drugs of the Future 26 2001 677-685
41. C.B. Juhl M. Hollingdal J. Sturis G. Jakobsen H. Agerso J. Veldhuis N. Porksen O. Schmitz Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 51 2002 424-429
42. U. Ribel M.O. Larsen B. Rolin R.D. Carr M. Wilken J. Sturis L. Westergaard C.F. Deacon L.B. Knudsen NN2211: A long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs Eur J Pharmacol 451 2002 217-225
43. K.B. Degn C.B. Juhl J. Sturis G. Jakobsen B. Brock V. Chandramouli J. Rungby B.R. Landau O. Schmitz One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187-1194
44. S. Madsbad O. Schmitz J. Ranstam G. Jakobsen D.R. Matthews Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care 27 2004 1335-1342
45. J.G. Kim L.L. Baggio D.P. Bridon J.P. Castaigne M.F. Robitaille L. Jette C. Benquet D.J. Drucker Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52 2003 751-759
46. B. Lawrence J. Dreyfus S. Wen P. Guicarc'h D. Drucker J.P. Castaigne CJC-ll31, a long acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers [abstract] Diabetes 52 Suppl 1 2003 A125
47. M. Bloom J. Bock A. Duttaroy K. Grzegorzewski P. Moor Y. Ou S. Wojcik X. Zhou A. Bell Albugon fusion protein: A long acting analogue of GLP-1 that provides lasting antidiabetic effect in animals [abstract] Diabetes 52 Suppl 1 2003 A112
48. C.F. Deacon M.A. Nauck M. Toft-Nielsen L. Pridal B. Willms J.J. Holst Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126-1131
49. C.F. Deacon T.E. Hughes J.J. Holst Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig Diabetes 47 1998 764-769
50. J.A. Pospisilik S.G. Stafford H.U. Demuth R. Brownsey W. Parkhouse D.T. Finegood C.H. McIntosh R.A. Pederson Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats Diabetes 51 2002 943-950
51. B. Sudre P. Broqua R.B. White D. Ashworth D.M. Evans R. Haigh J.L. Junien M.L. Aubert Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats Diabetes 51 2002 1461-1469
52. M.K. Reimer J.J. Holst B. Ahren Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice Eur J Endocrinol 146 2002 717-727
53. T. Nagakura N. Yasuda K. Yamazaki H. Ikuta S. Yoshikawa O. Asano I. Tanaka Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats Biochem Biophys Res Commun 284 2001 501-506
54. D. Marguet L. Baggio T. Kobayashi A.M. Bernard M. Pierres P.F. Nielsen U. Ribel T. Watanabe D.J. Drucker N. Wagtmann Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc Natl Acad Sci USA 97 2000 6874-6879
55. H. Mitani M. Takimoto M. Kimura Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity Jpn J Pharmacol 88 2002 451-458
56. H. Mitani M. Takimoto T.E. Hughes M. Kimura Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity Jpn J Pharmacol 88 2002 442-450
57. N. Yasuda T. Nagakura K. Yamazaki T. Inoue I. Tanaka Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats Life Sci 71 2002 227-238
58. S.L. Conarello Z. Li J. Ronan R.S. Roy L. Zhu G. Jiang F. Liu J. Woods E. Zycband D.E. Moller et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc Natl Acad Sci USA 100 2003 6825-6830
59. B. Ahren E. Simonsson H. Larsson M. Landin-Olsson H. Torgeirsson P.A. Jansson M. Sandqvist P. Bavenholm S. Efendic J.W. Eriksson et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869-875
60. B. Ahren M. Landin-Olsson P.A. Jansson M. Svensson D. Holmes A. Schweizer Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89 2004 2078-2084
61. R.E. Pratley E. Galbreath Twelve-week monotherapy qwith the DPP-4 inhibitor, LAF 237 improves glycemic control in patients with type 2 diabetes (T2DM) [abstract] Diabetes 53 Suppl 2 2004 A83
62. Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Prolonged efficacy of LAF237 in patients with type 2 diabetes (T2DM) inadequately treated with metformin [abstract]. 64th Scientific Sessions of the American Diabetes Association 2004. Orlando, USA
63. G.A. Herman P.L. Zhao B. Dietrich et al. The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics [abstract] Diabetes 53 Suppl 2 2004 A82
64. J. Heins K. Glund T. Hoffmann J. Metzner H.-U. Demuth The DP-IV inhibitor P93/01 improves glucose tolerance in humans with HbA1c gerater than 6.0 [abstract] Diabetes 53 Suppl 2 2004 A128
65. A.M. Lambeir C. Durinx S. Scharpe I. De Meester Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit Rev Clin Lab Sci 40 2003 209-294
66. L. Zhu C. Tamvakopoulos D. Xie J. Dragovic X. Shen J.E. Fenyk-Melody K. Schmidt A. Bagchi P.R. Griffin N.A. Thornberry R.R. Sinha The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38) J Biol Chem 278 2003 22418-22423
67. A. von Bonin J. Huhn B. Fleischer Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative T-cell activation pathway Immunol Rev 161 1998 43-53
68. B. Leiting E. Nichols T. Biftu S. Edmonson H. Ok A.E. Weber D. Zaller N.A. Thornberry Inhibition of dipeptidyl peptidase IV does not attenuate T cell activation in vitro [abstract] Diabetes 53 Suppl 2 2004 A2
69. G. Lankas B. Leiting R.S. Roy G. Eiermann T. Biftu D. Kim H. Ok A.E. Weber N.A. Thornberry Inhibition of DPP8/9 results in toxicity in preclinical species: Potential importance of selective dipeptidyl peptidase IV ionhibition for the treatment of type 2 DM (abstract] Diabetes 53 Suppl 2 2004 A2
70. A.E. Weber D. Kim M. Beconi et al. MK-0431 is a potent, selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [abstract] Diabetes 53 Suppl 2 2004 A151